DXB Chart, page-9

Let's be real here, this is a multiple phase 3 Biotech, one already commenced funded by the WHO, one due to commence in the coming days/weeks, and 2 in the planning/organising stage and we outstanding previous data, and our market cap is $50m. it is criminally undervalued. Yes a few (including me) was disappointed with the share price action after the last trial (which still garnered good results) we have been presented with the buying opportunity of a lifetime. I never expected to own any more DXB shares going into previous trial results but I've been accumulating like a mad man ever since. Unbelievable